Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03110822 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 study of Multiple Myeloma, sponsored by Oncotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
- 13
- Study locations
NCT03110822 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Oncotherapeutics. The registered enrollment target is 134 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% lower). The trial reports 13 study locations across 4 states.
The verdict
NCT03110822, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Oncotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Methylprednisolone
- DRUG Ruxolitinib Oral Tablet [Jakafi]
Study Locations (13)
California
- Global Oncology, Inc. - Alhambra
- Comprehensive Blood and Cancer Center - Bakersfield
- California Cancer Associates for Research & Excellence (cCARE) - Encinitas
- Compassionate Care Research Group, Inc. - Fountain Valley
- Robert A. Moss, M.D., F.A.C.P., Inc. - Fountain Valley
- Pacific Cancer Care - Monterey
- Sansum Clinic- Ridley-Tree Cancer Center - Santa Barbara
- Wellness Oncology and Hematology - West Hills
- James R. Berenson M.D. Inc. - West Hollywood
Florida
- Cancer Specialists, LLC - Jacksonville
- Millennium Oncology Research Clinic - Pembroke Pines
Maryland
- Regional Cancer Care Associates (RCCA) MD, LLC - Bethesda
Washington
- Northwest Medical Specialists, PPLC - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03110822
The ClinicalTrials.gov registry entry for NCT03110822 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (75% lower). The listed sponsor is Oncotherapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.
NCT03110822 reports 13 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT03110822 about?
NCT03110822 is a clinical study titled "A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients". This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
What is the current status of trial NCT03110822?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2017-02-01. Estimated completion is 2027-02.
What conditions does trial NCT03110822 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT03110822?
The interventions under investigation include: Lenalidomide (DRUG), Methylprednisolone (DRUG), Ruxolitinib Oral Tablet [Jakafi] (DRUG).
Who is sponsoring clinical trial NCT03110822?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03110822 being conducted?
This trial has 13 study locations across California, Florida, Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.